Anacor Pharmaceuticals

📍 Palo Alto, United States🗓 Founded 2002👥 32 employees💰 Last funded 2013
Pharmaceutical Manufacturing
LinkedIn
Anacor was a biopharmaceutical company focused on discovering, developing and commercializing novel small-molecule therapeutics derived from its boron chemistry platform. Anacor has discovered and is developing five clinical compounds, including its three lead programs: AN2690, a topical antifungal for the treatment of onychomycosis; AN2728, a topical anti-inflammatory PDE-4 inhibitor for the treatment of psoriasis; and GSK 2251052, or GSK '052 (formerly referred to as AN3365), a systemic antibiotic for the treatment of infections caused by Gram-negative bacteria, which has been licensed to GlaxoSmithKline under the companies'​ research and development agreement. In addition, Anacor is developing AN2718 as a topical antifungal product candidate for the treatment of onychomycosis and skin fungal infections, and AN2898 as a topical anti-inflammatory product candidate for the treatment of psoriasis and atopic dermatitis.
1
Total investors
0
Early stage
0
Mid stage
0
Late stage
2002
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
1
Frequently asked questions
Who invested in Anacor Pharmaceuticals?
Anacor Pharmaceuticals has 1 investors on record on gritt.io.
When did Anacor Pharmaceuticals last raise funding?
The most recent investment in Anacor Pharmaceuticals recorded on gritt.io was in 2013.
When was Anacor Pharmaceuticals founded?
Anacor Pharmaceuticals was founded in 2002.
What industry is Anacor Pharmaceuticals in?
Anacor Pharmaceuticals operates in Pharmaceutical Manufacturing. Find similar Pharmaceutical Manufacturing investors on gritt.io.
Where is Anacor Pharmaceuticals based?
Anacor Pharmaceuticals is headquartered in Palo Alto, United States.